Repare Therapeutics Inc.
RPTX
$2.12
-$0.01-0.24%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -82.16% | -99.64% | -98.90% | 4.58% | 18.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -82.16% | -99.64% | -98.90% | 4.58% | 18.19% |
| Cost of Revenue | -666.42% | -241.70% | -95.28% | 1.05% | -94.95% |
| Gross Profit | -20.42% | -73.52% | -99.53% | 5.82% | 186.46% |
| SG&A Expenses | -21.35% | -19.19% | -13.77% | -10.89% | -2.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.62% | -30.76% | -21.73% | -12.99% | -1.57% |
| Operating Income | 14.10% | -18.62% | -85.05% | 20.72% | 12.17% |
| Income Before Tax | 13.32% | -29.98% | -118.23% | 19.32% | 10.39% |
| Income Tax Expenses | -53.19% | 107.28% | 109.55% | 115.35% | -70.12% |
| Earnings from Continuing Operations | 14.10% | -60.34% | -179.90% | 9.71% | 13.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.10% | -60.34% | -179.90% | 9.71% | 13.73% |
| EBIT | 14.10% | -18.62% | -85.05% | 20.72% | 12.17% |
| EBITDA | 15.27% | -17.78% | -86.68% | 21.05% | 12.46% |
| EPS Basic | 14.59% | -59.16% | -177.18% | 10.59% | 14.41% |
| Normalized Basic EPS | 11.33% | -26.11% | -108.22% | 21.43% | 12.72% |
| EPS Diluted | 14.85% | -58.31% | -174.67% | 10.07% | 13.95% |
| Normalized Diluted EPS | 11.93% | -25.27% | -106.24% | 20.89% | 12.11% |
| Average Basic Shares Outstanding | 1.02% | 0.92% | 0.85% | 0.75% | 0.63% |
| Average Diluted Shares Outstanding | 0.01% | -0.14% | -0.21% | 1.82% | 1.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |